Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,558 questions in 115 reviews · Vascular
current versionsNo studies 346 · 22.2%Ungraded 90 · 5.8%Very low 281 · 18%Low 477 · 30.6%Moderate 313 · 20.1%High 51 · 3.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Direct thrombin inhibitors vs low molecular weight heparins Major VTE events bilateral ascending venography1 · patients with prevention of venous thromboembolism following total hip or knee replacement Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of… (2010) · Cochrane | OR 0.91 [0.69, 1.19] | 11 studies · 17428 participants | Low |
Direct thrombin inhibitors vs low molecular weight heparins All‐cause Mortality events · patients with prevention of venous thromboembolism following total hip or knee replacement Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of… (2010) · Cochrane | OR 2.06 [1.1, 3.87] | 11 studies · 22065 participants | Moderate |
Direct thrombin inhibitors vs low molecular weight heparins Total Bleeding events · patients with prevention of venous thromboembolism following total hip or knee replacement Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of… (2010) · Cochrane | OR 1.17 [0.98, 1.41] | 11 studies · 22109 participants | Low |
Direct thrombin inhibitors vs low molecular weight heparins ALT >3 times the upper normal limit · patients with prevention of venous thromboembolism following total hip or knee replacement Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of… (2010) · Cochrane | OR 0.41 [0.23, 0.72] | 7 studies · 12580 participants | Low |
Direct thrombin inhibitors vs vitamin K antagonists Major VTE events in TKR combined doses bilateral ascending venography · patients with prevention of venous thromboembolism following total hip or knee replacement Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of… (2010) · Cochrane | OR 0.85 [0.63, 1.15] | 3 studies · 4327 participants | Low |
Direct thrombin inhibitors vs vitamin K antagonists All‐cause Mortality events in TKR combined doses · patients with prevention of venous thromboembolism following total hip or knee replacement Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of… (2010) · Cochrane | OR 1.62 [0.57, 4.58] | 3 studies · 5243 participants | Low |
Direct thrombin inhibitors vs vitamin K antagonists Total Bleeding events in TKR combined doses · patients with prevention of venous thromboembolism following total hip or knee replacement Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of… (2010) · Cochrane | OR 1.26 [0.97, 1.62] | 3 studies · 5259 participants | Low |
Direct thrombin inhibitors vs vitamin K antagonists ALT >3 times the upper normal limit at the end of · patients with prevention of venous thromboembolism following total hip or knee replacement Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of… (2010) · Cochrane | OR 5.61 [1, 31.64] | 2 studies · 4267 participants | Low |